Paediatric Respiratory Medicine

Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]

touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]

The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]

Nintedanib is an inhibitor of tyrosine kinases involved in the progression of pulmonary fibrosis and blocks the signalling pathways involved in fibrotic processes. We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) around the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung […]

Respiratory syncytial virus (RSV) is a ubiquitous virus that causes annual epidemics of infection in young children in all parts of the world. In temperate regions, epidemics are seasonal, and predictable during the winter months. Approximately half of all infants develop their first RSV infection prior to their first birthday. By 24 months of age, […]